About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

DZD9008 PK Study in Hepatic Impairment Subjects | Clinical Trials | Clareo Health

COMPLETEDPhase 1

DZD9008 PK Study in Hepatic Impairment Subjects

A Phase 1, Single-Dose, Non-Randomized, Open Label Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of DZD9008

NCT06084104•Dizal Pharmaceuticals

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Hepatic Impairment

Interventions

DZD9008

DZD9008

Locations

2

United States

Locations (2)

Orlando Clinical Research Center

Orlando, Florida, United States

American Research Corporation

San Antonio, Texas, United States

Key Dates

Start Date

October 17, 2023

Primary Completion Date

June 12, 2024

Completion Date

October 23, 2024

Last Updated

December 18, 2024

Related Studies

RECRUITINGPhase 1

A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment

NCT07324616

Hepatic Impairment (HI)

RECRUITINGPhase 1

Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants

NCT04271488

Hepatic Impairment

RECRUITINGPhase 1

An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage

NCT06952634

Hepatic Impairment

COMPLETEDPhase 1

A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function

NCT07428525

Hepatic Impairment

COMPLETEDPhase 1

A Varegacestat Hepatic Impairment Study

NCT06841315

Healthy VolunteerHepatic Impairment (HI)

COMPLETEDPhase 1

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of KP-001

NCT06619054

Healthy AdultsHepatic Impairment

View all related studies

Sponsors

Lead Sponsor

Dizal Pharmaceuticals

Collaborators

PPD Development, L.P.

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 18, 2024Data synced to Clareo: April 27, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions